Full View

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti‐Passerini, JE Cortes… - American journal of …, 2014 - Wiley Online Library
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …
被引用次数：117 相关文章
[HTML] nih.gov

[HTML][HTML] Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti-Passerini, JE Cortes… - American Journal of …, 2014 - ncbi.nlm.nih.gov
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti‐Passerini, JE Cortes, JH Lipton… - American Journal of …, 2014 - cir.nii.ac.jp
抄録< jats: p> Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated
clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP …

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti-Passerini, JE Cortes… - American Journal …, 2014 - augusta.elsevierpure.com
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

C Gambacorti-Passerini, JE Cortes… - American Journal of …, 2014 - europepmc.org
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

[引用][C] Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti-Passerini, JE Cortes… - American Journal of …, 2014 - elibrary.ru

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C GAMBACORTI PASSERINI, J Cortes… - AMERICAN JOURNAL …, 2014 - boa.unimib.it
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti-Passerini, JE Cortes… - American journal …, 2014 - pubmed.ncbi.nlm.nih.gov
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti-Passerini… - American journal …, 2014 - mdanderson.elsevierpure.com
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

C Gambacorti‐Passerini, JE Cortes, JH Lipton… - American Journal of …, 2014 - infona.pl
Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …